Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Expert Opinion on Drug Safety|October 13, 2016
A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management systemAmy Tanti, Benjamin Micallef, Anthony Serracino-Inglott, et al.
Frontiers in Pharmacology|June 19, 2023
Alzheimer's disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?Daniela Melchiorri, Sara Merlo, Benjamin Micallef, et al.
Expert Opinion on Drug Safety|October 15, 2021
Improving the data quality of spontaneous ADR reports: a practical example from MaltaMarta Zuccarelli, Benjamin Micallef, Dianne Butler, et al.
Current Medical Research and Opinion|May 27, 2022
QT shortening: a proarrhythmic safety surrogate measure or an inappropriate indicator of it?Amy Tanti, Benjamin Micallef, Janis Vella Szijj, et al.
The International Journal of Risk & Safety in Medicine|May 31, 2024
An exploratory study of knowledge, attitudes, practice and barriers towards adverse drug reaction reporting among healthcare professionals in MaltaElisa Curtolo, Benjamin Micallef, Janis Vella Szijj, et al.
Drug Metabolism and Personalized Therapy|May 31, 2019
Regulatory sciences and translational pharmacogenetics: amitriptyline as a case in pointLuana Mifsud Buhagiar, Benjamin Micallef, John Joseph Borg, et al.
Expert Opinion on Drug Safety|April 12, 2021
Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EUDianne Butler, Katarina Vucic, Sabine Straus, et al.
The Journal of Pharmacy Technology : Jpt : Official Publication of the Association of Pharmacy Technicians|March 25, 2024
Nivolumab Safety in Renal Cell Carcinoma: A Case ReportJames Debono, Dustin Balzan, John Joseph Borg, et al.
The International Journal of Risk & Safety in Medicine|September 9, 2017
Opinions of Maltese doctors and pharmacists on medication errorsAmy Tanti, Miriam Camilleri, Andrew A Borg, et al.
Drug Discovery Today|May 21, 2022
Outcomes and endpoints in clinical trials supporting the marketing authorisation of treatments in paediatric acute lymphoblastic leukaemiaBenjamin Micallef, Robert Nistico, Ole Weis Bjerrum, et al.
Pageof 2